Why These Trials Matter

Two landmark Italian clinical trials—GISSI‑Prevenzione (1999) and GISSI‑HF (2008)—tested whether 1 gram per day of EPA+DHA omega‑3s could improve survival in nearly 20,000 patients with severe heart disease or chronic heart failure. Their findings established foundational evidence for cardiovascular nutrition.

Key Clinical Findings

GISSI‑Prevenzione (11,324 Post-Heart Attack Patients)

Following patients for 3.5 years on 1 g/day EPA+DHA or standard care alone showed rapid benefits:

• 20% reduction in all‑cause mortality
• 45% reduction in sudden cardiac death

GISSI‑HF (6,975 Chronic Heart Failure Patients)

A double-blind, placebo-controlled trial evaluating 1 g/day EPA+DHA alongside modern heart-failure medications showed:

• 9% reduction in all‑cause mortality
• 8% reduction in cardiovascular hospitalizations

Mechanisms of Action

Omega-3 fatty acids exert protective cardiovascular effects through several key pathways:

• Anti-arrhythmic activity: Stabilizes cardiac electrical signals, reducing risk of fatal arrhythmias.
• Vascular support: Reduces systemic inflammation and enhances endothelial vasodilatory response.
• Lipid modulation: Helps regulate serum triglycerides.

Practical Takeaways

While omega-3s do not replace standard prescription therapies, these trials demonstrate that consistent daily intake offers clinically meaningful support. Aim for a food-first strategy by consuming fatty fish (salmon, sardines, mackerel) twice weekly, or discuss targeted supplementation with a healthcare provider.

Reference

GISSI‑Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction (GISSI-Prevenzione trial). Lancet. 1999;354(9177):447–455.

GISSI‑HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial). Lancet. 2008;372(9645):1223–1230.